Key points from article :
Experimental natural killer cell (NK) therapy is showing promising results in the treatment of Alzheimer's in a small phase 1 trial.
NKGen Biotech's SNK01 is a nongenetically modified NK cell product that has enhanced cytotoxicity and activating receptor expression.
SNK01 targets both amyloid and tau proteins, potentially slowing disease progression and even improving cognitive function.
"In the first 6 months, 90% of AD patients maintained or improved cognitive function," - Paul Song, CEO of NKGen Biotech.
SNK01 appears to cross the blood-brain barrier and reach affected brain tissue.
NK cells were successfully expanded in all 10 patients and no adverse events were observed.
The US FDA approved a phase 1/2a study in patients with higher doses and prolonged treatment is planned.
Combining SNK01 with other AD therapies like anti-amyloid or anti-tau drugs could be beneficial, said Song.
